Skip to content

Is Ozempic safe? What the GLP-1 labels and FDA say

By the glp1doses editorial team
Every number is checked against FDA labels and official price pages. How we check

The short answer

Is Ozempic safe? It's an FDA-approved medicine whose label sets out its known risks, and whether it's right for you is a decision for you and your prescriber. Every GLP-1 label we track, Ozempic's included, carries a boxed warning about thyroid C-cell tumors and a contraindication for people with a personal or family history of medullary thyroid carcinoma or MEN 2. FDA has also warned about dosing errors with compounded semaglutide.

Source: U.S. Food and Drug Administration

Key takeaways

  • Every GLP-1 label we track, Ozempic's included, has a boxed warning about thyroid C-cell tumors.
  • These medicines are not to be used with a personal or family history of medullary thyroid carcinoma or MEN 2.
  • Multi-dose pens must never be shared between patients, even if the needle is changed.
  • Took too much? Call Poison Help at 1-800-222-1222. Call 911 for trouble breathing, collapse, passing out or a seizure.
  • FDA advises buying only from state-licensed pharmacies, with a valid prescription.

GLP-1 medicines are prescription drugs with long FDA labels. The safety sections of those labels are the most reliable record of what’s known. This guide brings together what the labels of the eight products we track say: Zepbound, Mounjaro, Foundayo, Trulicity, Wegovy, Ozempic, Rybelsus and Saxenda. It adds FDA’s alerts about dosing errors, counterfeit pens and unapproved products.

Think of it as a map, not medical advice. Whether one of these medicines is right for you is a decision for you and your prescriber.

What is the boxed warning on Ozempic and other GLP-1 medicines?

A boxed warning, often called a black box warning, is the most prominent warning FDA puts on a label. All eight labels in our records carry one, with the same heading: risk of thyroid C-cell tumors.

The warning is based on animal studies. The Zepbound label says that in rats, tirzepatide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures. In plain words, higher doses and longer use meant more tumors in the rats, at exposures the label calls clinically relevant. The semaglutide labels (Wegovy, Ozempic, Rybelsus) say the same of semaglutide in rodents. The Saxenda label says it of liraglutide in rats and mice, and the Trulicity label says it of dulaglutide in rats after lifetime exposure.

Each of those labels then says the same thing about people. It’s unknown whether the medicine causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans, because the human relevance of the rodent findings has not been determined.

Foundayo’s label is worded differently. Its boxed warning says rodent thyroid C-cell tumors have been seen with products that have GLP-1 receptor agonist activity and are pharmacologically active in rats and mice. It then says orforglipron is not pharmacologically active in rats or mice and did not produce tumors in rodents. The warning and the contraindication still apply to Foundayo.

What the boxed warning means in practice is the first contraindication on every label, covered next.

Who should not take a GLP-1?

The labels make three kinds of statement. Contraindications mean do not use. Then there are limitations and “not recommended” statements. Last come warnings that call for monitoring.

Contraindications. All eight labels list the same two:

  • a personal or family history of medullary thyroid carcinoma, or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
  • a serious hypersensitivity (allergic) reaction to the active ingredient or any of the product’s other ingredients. The semaglutide and liraglutide labels note that serious reactions, including anaphylaxis and angioedema, have been reported.

Not recommended.

  • Severe gastroparesis. The Zepbound, Mounjaro, Foundayo and Trulicity labels say the medicine is not recommended in patients with severe gastroparesis (a stomach that empties very slowly). The Wegovy, Ozempic, Rybelsus and Saxenda warning sections say the same.
  • Severe liver impairment. Foundayo is not recommended in patients with severe hepatic (liver) impairment (Child-Pugh Class C). The Trulicity label says clinical experience in hepatic impairment is limited and to use it with caution.
  • Another GLP-1 at the same time. See the section on combining medicines below.

Children. The safety and effectiveness of Zepbound and of Foundayo have not been established in pediatric patients. For Mounjaro and Trulicity, they have not been established in patients under 10 years of age.

The page on who should not take a GLP-1 goes through this drug by drug.

Are GLP-1s safe? The serious risks the labels warn about

Beyond the boxed warning, the warnings sections of the labels cover a consistent list. Our side-effect records hold the warnings below, each on most or all of the eight labels.

  • Acute pancreatitis. Inflammation of the pancreas has been seen with GLP-1 receptor agonists, including fatal cases. The labels say to discontinue the medicine if pancreatitis is suspected. The Ozempic label describes the symptom to watch for as persistent or severe abdominal pain, sometimes radiating to the back, with or without nausea or vomiting.
  • Severe gastrointestinal reactions. Stomach and bowel side effects are sometimes severe.
  • Acute kidney injury due to volume depletion. Reported mostly in people who became dehydrated from nausea, vomiting or diarrhea, in some cases needing hemodialysis.
  • Acute gallbladder disease. Gallstones and gallbladder inflammation.
  • Hypoglycemia. A higher risk of low blood sugar when the medicine is used with insulin or a sulfonylurea.
  • Hypersensitivity reactions. Serious allergic reactions such as anaphylaxis and angioedema.
  • Diabetic retinopathy complications. Flagged for people with type 2 diabetes, particularly those with a history of retinopathy (damage to the back of the eye).
  • NAION, a rare cause of sudden vision loss. In November 2026, FDA said GLP-1 receptor agonists carry a potential increased risk of non-arteritic anterior ischemic optic neuropathy (NAION). It is a rare condition that can cause sudden, painless loss of vision in one eye, sometimes permanently. FDA is requiring every GLP-1 label to add it to the warnings section, so the label in your box may not show it yet. Contact your healthcare professional right away if the vision in one eye suddenly changes.
  • Pulmonary aspiration during general anesthesia or deep sedation. Because these medicines delay gastric emptying, there have been rare reports with GLP-1 receptor agonists of stomach contents getting into the lungs. The Ozempic, Rybelsus and Saxenda labels say to tell your healthcare providers before any planned surgery or procedure that you take the medicine.
  • Heart rate increase. A named warning on the Wegovy and Saxenda labels.
  • Never share a pen. The multi-dose pens (Ozempic, Saxenda, the Zepbound and Mounjaro KwikPens, the Wegovy FlexTouch) must never be shared between patients, even if the needle is changed, because of the risk of passing on infection.

How often the common reactions happened in each label’s trials is set out, with the tables, in the side effects guide.

Can you take a GLP-1 if you are pregnant, planning to be, or breastfeeding?

The labels take pregnancy seriously, and the wording depends on what the medicine is for.

For the weight-management products, the labels say weight loss offers no benefit to a pregnant patient and may cause fetal harm. Zepbound, Foundayo, Saxenda and Wegovy (when used for weight reduction) are to be discontinued when a pregnancy is recognized. For the diabetes products Mounjaro and Trulicity, the labels say the medicine should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

The semaglutide labels add a lead time. Wegovy, Ozempic, Ozempic tablets and Rybelsus are to be discontinued at least 2 months before a planned pregnancy. The reason is semaglutide’s long half-life and washout period, meaning it takes a long time to leave the body. The Saxenda label gives no such interval.

The tablet labels address breastfeeding. Breastfeeding is not recommended during treatment with Wegovy tablets, Ozempic tablets or Rybelsus, and Foundayo is not recommended for nursing women.

The details, including the birth control advice on the tirzepatide and Foundayo labels, are on the pregnancy and breastfeeding page.

Which drug interactions matter?

Three themes run through the labels.

  1. Insulin and sulfonylureas. Most labels say to consider lowering the dose of insulin or a sulfonylurea when starting the GLP-1, to reduce the risk of hypoglycemia. The Wegovy label notes that adding Wegovy for patients treated with insulin has not been evaluated.
  2. Other oral medicines. All of these medicines delay gastric emptying, which can change how other medicines taken by mouth are absorbed. The Trulicity label says to monitor drug levels of oral medicines with a narrow therapeutic index, such as warfarin. That means medicines where a small change in the level in your blood can matter. The semaglutide tablet label reports a rise in levothyroxine exposure in an interaction study.
  3. Birth control pills. The Zepbound and Mounjaro labels advise a non-oral method, or adding a barrier method, for 4 weeks after starting and after each dose escalation (dose increase). Foundayo’s label advises the same for 30 days.

Foundayo has interactions the injectables don’t. Its label says to avoid strong CYP3A4 inducers and certain strong CYP3A4 inhibitors, two groups of medicines that change how the body breaks down other drugs. It also caps simvastatin at 20 mg once daily. The drug interactions page has the detail for each medicine and the recorded hypoglycemia figures.

Can you combine two GLP-1 medicines?

The labels say it is not recommended.

  • Zepbound: using it with other tirzepatide-containing products or with any GLP-1 receptor agonist is not recommended.
  • Wegovy: not recommended with other semaglutide-containing products or with any other GLP-1 receptor agonist.
  • Saxenda: not recommended with other liraglutide-containing products or any other GLP-1 receptor agonist.
  • Foundayo: use with another GLP-1 receptor agonist is not recommended.

Two brands can contain one molecule. Zepbound and Mounjaro both contain tirzepatide, and Wegovy, Ozempic and Rybelsus all contain semaglutide. Each has its own label and approved uses, and the statements above mean they are not taken together. Moving from one to another is a decision for your prescriber. The switching planner shows what the labels say about it.

What are GLP-1 dosing errors?

Taking the wrong amount, usually too much. The risk is highest with products drawn up from a vial with a syringe.

FDA issued an alert on July 26, 2024 after receiving reports of adverse events, some needing a hospital stay, that may be related to overdoses from dosing errors with compounded injectable semaglutide. Most reports described patients drawing up more than the prescribed dose from a multiple-dose vial, and those patients took five to 20 times the intended dose. FDA pointed to confusion between milliliters, milligrams and “units”, and to unfamiliarity with syringes. In some reports the prescriber made the conversion error, giving doses five to 10 times higher than intended.

FDA contrasts this with the approved products. FDA-approved injectable semaglutide is dosed in milligrams, has standard concentrations and, in the words of the alert, is available only in pre-filled pens.

Errors happen with approved pens too. America’s Poison Centers says poison centers are most often contacted about accidental therapeutic errors with FDA-approved GLP-1 drugs, such as taking doses too close together or taking a higher than recommended dose at once. It reports 22,966 GLP-1 agonist related exposure cases from 2019 to 2025, and notes that an exposure is not necessarily a poisoning or overdose.

If you think you’ve taken too much, call Poison Help at 1-800-222-1222. The dosing errors page explains the alerts. The units, mL and mg tool shows how the three measurements relate, so you can check an instruction with your pharmacist.

Counterfeit and unapproved products

Counterfeit Ozempic. FDA says it is aware of counterfeit Ozempic sold in the U.S. Counterfeits claim to be authentic but could contain the wrong ingredients, too little, too much or no active ingredient, or other harmful ingredients. In its December 5, 2025 update, FDA said it had seized dozens of units of counterfeit Ozempic 1 mg labeled with lot number PAR1229, which is also a real lot number. You can spot the counterfeit by the EXP/LOT text, which sits to the left of the expiration date and lot number. On the authentic pen it sits above them. In an earlier seizure, FDA found the needles were counterfeit too, so their sterility couldn’t be confirmed.

Fraudulent compounded products. FDA also knows of fraudulent compounded semaglutide and tirzepatide with false information on the label, including compounding pharmacies that don’t exist.

“Research use” products. FDA has warned companies illegally selling unapproved semaglutide, tirzepatide, retatrutide, survodutide or mazdutide falsely labeled “for research purposes” or “not for human consumption.” The agency urges consumers not to buy these products, which are of unknown quality and may be harmful.

Compounded drugs generally. FDA says compounded drugs are not FDA approved, which means the agency does not review them for safety, effectiveness or quality before they are marketed. By May 31, 2026, FDA had received 990 reports of adverse events linked to compounded semaglutide and more than 730 linked to compounded tirzepatide, and it says such events are likely underreported.

FDA’s advice stays the same throughout: buy only from state-licensed pharmacies, with a valid prescription. The compounded GLP-1 guide covers the rules, and the cost guide lists the legitimate routes to the approved products, including manufacturer self-pay programs.

How to report a problem

MedWatch is FDA’s program for reporting serious reactions, product quality problems and mistakes in how a product was used. You can fill in the online form yourself. FDA’s information line is 1-888-INFO-FDA (1-888-463-6332). For compounded GLP-1 products in particular, FDA encourages patients, health care professionals and compounders to report adverse events or quality problems to MedWatch.

Frequently asked questions

What is the boxed warning on GLP-1 medicines?

It's a warning about thyroid C-cell tumors. The labels say semaglutide, tirzepatide, liraglutide and dulaglutide caused these tumors in rodents, and that it's unknown whether the medicines cause them in humans, including medullary thyroid carcinoma. Foundayo carries the same boxed warning heading, although its label says orforglipron did not produce tumors in rodents.

Who should not take a GLP-1?

All eight labels we track list two contraindications, meaning situations where the medicine must not be used. One is a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. The other is a serious hypersensitivity (allergic) reaction to the drug or its ingredients. Several labels also say the medicine is not recommended with severe gastroparesis. Your prescriber weighs everything else.

Can you take a GLP-1 while pregnant?

The labels for the weight-management products (Zepbound, Wegovy, Foundayo and Saxenda) say weight loss offers no benefit to a pregnant patient and may cause fetal harm. They say the medicine is stopped when a pregnancy is recognized. The semaglutide labels say to stop at least 2 months before a planned pregnancy. Talk to your prescriber if you're pregnant or planning to be.

Does Zepbound make birth control pills less effective?

The Zepbound label says it may make oral hormonal contraceptives (birth control pills) less effective, because it slows how fast the stomach empties. It advises switching to a non-oral method, or adding a barrier method, for 4 weeks after starting and for 4 weeks after each dose increase. The Mounjaro label says the same. Foundayo's label gives the same advice for 30 days.

What should I do if I took too much semaglutide or tirzepatide?

America's Poison Centers says that for questions about GLP-1 medicines and overdoses, you can call Poison Help at 1-800-222-1222. The call costs nothing, and the line is open around the clock. The Poison Help site says to call 911 right away if a person has trouble breathing, collapses or loses consciousness, or has a seizure.

How do I know my Ozempic is not counterfeit?

FDA says to get Ozempic only with a valid prescription through a state-licensed pharmacy, and to check the product for signs of counterfeiting before you use it. In its December 5, 2025 update, FDA described counterfeit 1 mg pens labeled with lot number PAR1229. On those, the EXP/LOT text sits to the left of the expiration date and lot number instead of above them.

Can I take two GLP-1 medicines together?

The labels say this is not recommended. Zepbound should not be used with other tirzepatide-containing products or any GLP-1 receptor agonist. Wegovy is not recommended with other semaglutide-containing products or any other GLP-1 receptor agonist. The Saxenda and Foundayo labels say the same in their own words. Switching from one to another is a decision for your prescriber.

How do I report a side effect or a bad product to FDA?

Through MedWatch, FDA's safety reporting program. You can fill in the online reporting form yourself, and you don't need a health care provider to do it. FDA's information line is 1-888-INFO-FDA (1-888-463-6332). Press 2 to report into MedWatch or to get instructions. FDA wants reports of adverse events (side effects) and of quality problems.

Is Zepbound safe?

The Zepbound label doesn't answer with a yes or no. It carries the boxed warning about thyroid C-cell tumors, which rests on studies of tirzepatide in rats. It's contraindicated (must not be used) in people with a personal or family history of medullary thyroid carcinoma or with MEN 2, and it's not recommended in severe gastroparesis. Whether it's right for you is a decision for you and your prescriber.

Is semaglutide safe?

FDA-approved semaglutide (Wegovy, Ozempic and Rybelsus) carries the boxed warning and the other warnings on this page. FDA treats those products separately from compounded semaglutide. Compounded semaglutide is not FDA approved, and FDA doesn't review it for safety, effectiveness or quality before it's sold. FDA's dosing error alert was about compounded injectable semaglutide drawn up from vials.

Sources (74)

  1. 1.
    Zepbound prescribing information, boxed warning
    “In rats, tirzepatide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures. It is unknown whether ZEPBOUND causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as human relevance of tirzepatide-induced rodent thyroid C-cell tumors has not been determined [see Warnings and Precautions (5.1) and Nonclinical Toxicology (13.1)].”
  2. 2.
    Wegovy prescribing information, boxed warning
    “In rodents, semaglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures. It is unknown whether WEGOVY causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as human relevance of semaglutide-induced rodent thyroid C-cell tumors has not been determined”
  3. 3.
    Foundayo prescribing information, boxed warning
    “In products with glucagon-like peptide-1 (GLP-1) receptor agonist activity that are pharmacologically active in rats and mice, rodent thyroid C-cell tumors (adenomas and carcinomas) have been observed at clinically relevant exposures and are considered GLP-1 receptor-dependent effects in rodents. Orforglipron is not pharmacologically active in rats or mice and did not produce tumors in rodents [see Nonclinical Toxicology (13.1)].”
  4. 4.
    FDA alerts health care providers, compounders and patients of dosing errors associated with compounded injectable semaglutide products
    “The majority of the reports described patients mistakenly drawing up more than the prescribed dose from a multiple-dose vial during self-administration. In these instances, patients administered five to 20 times more than the intended dose of semaglutide. Most of the reports indicated that patients were unfamiliar with how to measure the intended dose using a syringe.”
  5. 5.
    FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss
    “FDA is aware of counterfeit Ozempic marketed in the U.S. Counterfeit drugs claim to be authentic, but could contain the wrong ingredients, contain too little, too much or no active ingredient at all or other harmful ingredients, and are illegal.”
  6. 6.
    FDA warns consumers not to use counterfeit Ozempic (semaglutide) found in U.S. drug supply chain
    “Patients should only obtain Ozempic with a valid prescription through state-licensed pharmacies and check the product before using for any signs of counterfeiting.”
  7. 7.
    America's Poison Centers - GLP-1
    “Poison Centers are most often contacted about accidental therapeutic errors to FDA- approved GLP-1 drugs. Common mistakes include taking doses too closely together or taking a higher than recommended dose at once. With compounded products, patients report accidentally taking 10-times the recommended dose due to confusing measurement units while using a syringe.”
  8. 8.
    Reporting Serious Problems to FDA
    “If you need information or if you have questions or comments about a medical product, please call the FDA's toll-free information line, 1-888-INFO-FDA (1-888-463-6332) Press 2 to report into MedWatch or for instructions.”
  9. 9.
    U.S. Food and Drug Administration: FDA Requires Safety Labeling Changes for Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) Due to Potential Increased Risk of Rare But Serious Eye Condition
    “The U.S. Food and Drug Administration is informing patients and health care providers of a potential increased risk of non-arteritic anterior ischemic optic neuropathy (NAION) associated with use of glucagon-like peptide-1 receptor agonist (GLP-1 RA) medications. NAION is a rare condition that can result in acute, painless, decreased vision in one eye, including permanent vision loss. [...] The agency is requiring application holders for all GLP-1 RA medications to add information to the Warnings and Precautions section of labeling about the potential increased risk of NAION associated with use of these medications. [...] Patients should contact their health care professional right away if they have any of these symptoms. If a patient has had a NAION event, they should talk with their health care professional about whether to continue taking their GLP-1 RA medication or to stop it.”
  10. 10.
    FDA label (DailyMed): Zepbound prescribing information, section 4
    “ZEPBOUND is contraindicated in patients with: A personal or family history of MTC or in patients with MEN 2 [see Warnings and Precautions (5.1)].”
  11. 11.
    FDA label (DailyMed): Zepbound prescribing information, section 4
    “ZEPBOUND is contraindicated in patients with: Known serious hypersensitivity to tirzepatide or any of the excipients in ZEPBOUND.”
  12. 12.
    FDA label (DailyMed): Zepbound prescribing information, section 1
    “ZEPBOUND contains tirzepatide. Coadministration with other tirzepatide-containing products or with any glucagon-like peptide-1 (GLP-1) receptor agonist is not recommended.”
  13. 13.
    FDA label (DailyMed): Zepbound prescribing information, section 5.2
    “ZEPBOUND is not recommended in patients with severe gastroparesis.”
  14. 14.
    FDA label (DailyMed): Zepbound prescribing information, section 8.4
    “The safety and effectiveness of ZEPBOUND have not been established in pediatric patients.”
  15. 15.
    FDA label (DailyMed): Zepbound prescribing information, section 8.1
    “Weight loss offers no benefit to a pregnant patient and may cause fetal harm. Advise pregnant patients that weight loss is not recommended during pregnancy and to discontinue ZEPBOUND when a pregnancy is recognized (see Clinical Considerations).”
  16. 16.
    FDA label (DailyMed): Zepbound prescribing information, section 8.3
    “Use of ZEPBOUND may reduce the efficacy of oral hormonal contraceptives due to delayed gastric emptying. This delay is largest after the first dose and diminishes over time. Advise patients using oral hormonal contraceptives to switch to a non-oral contraceptive method, or add a barrier method of contraception for 4 weeks after initiation with ZEPBOUND and for 4 weeks after each dose escalation [see Drug Interactions (7.2) and Clinical Pharmacology (12.2, 12.3)].”
  17. 17.
    FDA label (DailyMed): Zepbound prescribing information, section 7.1
    “ZEPBOUND lowers blood glucose. When initiating ZEPBOUND, consider reducing the dose of concomitantly administered insulin or insulin secretagogues (e.g., sulfonylureas) to reduce the risk of hypoglycemia [see Warnings and Precautions (5.7)].”
  18. 18.
    FDA label (DailyMed): Zepbound prescribing information, section 7.2
    “ZEPBOUND delays gastric emptying and thereby has the potential to impact the absorption of concomitantly administered oral medications. Caution should be exercised when oral medications are concomitantly administered with ZEPBOUND.”
  19. 19.
    FDA label (DailyMed): Mounjaro prescribing information, section 4
    “MOUNJARO is contraindicated in patients with: A personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) [see Warnings and Precautions (5.1)].”
  20. 20.
    FDA label (DailyMed): Mounjaro prescribing information, section 4
    “MOUNJARO is contraindicated in patients with: Known serious hypersensitivity to tirzepatide or any of the excipients in MOUNJARO.”
  21. 21.
    FDA label (DailyMed): Mounjaro prescribing information, section 5.6
    “MOUNJARO is not recommended in patients with severe gastroparesis.”
  22. 22.
    FDA label (DailyMed): Mounjaro prescribing information, section 8.1
    “MOUNJARO should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.”
  23. 23.
    FDA label (DailyMed): Mounjaro prescribing information, section 8.3
    “Use of MOUNJARO may reduce the efficacy of oral hormonal contraceptives due to delayed gastric emptying. This delay is largest after the first dose and diminishes over time. Advise patients using oral hormonal contraceptives to switch to a non-oral contraceptive method or add a barrier method of contraception for 4 weeks after initiation and for 4 weeks after each dose escalation with MOUNJARO [see Drug Interactions (7.2) and Clinical Pharmacology (12.2, 12.3)].”
  24. 24.
    FDA label (DailyMed): Foundayo prescribing information, section 4
    “FOUNDAYO is contraindicated in patients with: A personal or family history of MTC or in patients with MEN 2 [see Warnings and Precautions (5.1)].”
  25. 25.
    FDA label (DailyMed): Foundayo prescribing information, section 4
    “FOUNDAYO is contraindicated in patients with: Known serious hypersensitivity to orforglipron or any of the excipients in FOUNDAYO.”
  26. 26.
    FDA label (DailyMed): Foundayo prescribing information, section 1
    “Concomitant use with another GLP-1 receptor agonist is not recommended.”
  27. 27.
    FDA label (DailyMed): Foundayo prescribing information, section 5.3
    “FOUNDAYO is not recommended in patients with severe gastroparesis.”
  28. 28.
    FDA label (DailyMed): Foundayo prescribing information, section 8.6
    “FOUNDAYO is not recommended for use in patients with severe hepatic impairment (Child-Pugh Class C) [see Clinical Pharmacology (12.3)].”
  29. 29.
    FDA label (DailyMed): Foundayo prescribing information, section 8.1
    “Weight loss offers no benefit to a pregnant patient and may cause fetal harm. When a pregnancy is recognized, advise the pregnant patient of the risk to a fetus and discontinue FOUNDAYO.”
  30. 30.
    FDA label (DailyMed): Foundayo prescribing information, section 8.2
    “FOUNDAYO is not recommended for nursing women.”
  31. 31.
    FDA label (DailyMed): Foundayo prescribing information, section 7.3
    “Advise patients using oral hormonal contraceptives to switch to a non-oral contraceptive method or add a barrier method of contraception for 30 days after initiation with FOUNDAYO and for 30 days after each dose escalation. Hormonal contraceptives that are not administered orally should not be affected.”
  32. 32.
    FDA label (DailyMed): Foundayo prescribing information, section 2.2
    “Avoid strong CYP3A4 inhibitors that also inhibit OATP1B when taking FOUNDAYO. Avoid strong CYP3A4 inducers when taking FOUNDAYO.”
  33. 33.
    FDA label (DailyMed): Foundayo prescribing information, section 7.2, Table 3
    “Do not exceed simvastatin 20 mg once daily when concomitantly used with FOUNDAYO.”
  34. 34.
    FDA label (DailyMed): Trulicity prescribing information, section 4
    “TRULICITY is contraindicated in patients with: Personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) [see Warnings and Precautions (5.1)].”
  35. 35.
    FDA label (DailyMed): Trulicity prescribing information, section 4
    “TRULICITY is contraindicated in patients with: Serious hypersensitivity reaction to dulaglutide or to any of the product components.”
  36. 36.
    FDA label (DailyMed): Trulicity prescribing information, section 5.6
    “TRULICITY is not recommended in patients with severe gastroparesis.”
  37. 37.
    FDA label (DailyMed): Trulicity prescribing information, section 8.1
    “TRULICITY should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.”
  38. 38.
    FDA label (DailyMed): Trulicity prescribing information, section 7.1
    “Monitor drug levels of oral medications with a narrow therapeutic index (e.g., warfarin) when concomitantly administered with TRULICITY.”
  39. 39.
    FDA label (DailyMed): Wegovy prescribing information, section 4
    “a personal or family history of MTC or in patients with MEN 2”
  40. 40.
    FDA label (DailyMed): Wegovy prescribing information, section 4
    “a prior serious hypersensitivity reaction to semaglutide or to any of the excipients in WEGOVY injection or WEGOVY tablet. Serious hypersensitivity reactions, including anaphylaxis and angioedema, have been reported with WEGOVY”
  41. 41.
    FDA label (DailyMed): Wegovy prescribing information, section 1
    “Concomitant use of WEGOVY (semaglutide) tablets or WEGOVY (semaglutide) injection with other semaglutide-containing products or with any other GLP-1 receptor agonist is not recommended.”
  42. 42.
    FDA label (DailyMed): Wegovy prescribing information, section 8.3
    “Because of the potential for fetal harm, discontinue WEGOVY in patients at least 2 months before they plan to become pregnant to account for the long half-life of semaglutide”
  43. 43.
    FDA label (DailyMed): Wegovy prescribing information, section 8.1
    “Weight loss offers no benefit to a pregnant patient and may cause fetal harm. When a pregnancy is recognized, advise the pregnant patient of the risk to a fetus. Discontinue WEGOVY in pregnant patients who are using it for weight reduction”
  44. 44.
    FDA label (DailyMed): Wegovy prescribing information, section 17
    “Advise females not to breastfeed during treatment with WEGOVY tablets”
  45. 45.
    FDA label (DailyMed): Wegovy prescribing information, section 7.1
    “The risk of hypoglycemia is increased when WEGOVY is used concomitantly with insulin or insulin secretagogues (e.g., sulfonylureas). The addition of WEGOVY in patients treated with insulin has not been evaluated.”
  46. 46.
    FDA label (DailyMed): Wegovy prescribing information, section 7.2
    “In a drug interaction study with the semaglutide tablet, levothyroxine exposure was increased 33% (90% CI: 1.25-1.42). Monitor the effects of oral medications concomitantly administered with WEGOVY.”
  47. 47.
    FDA label (DailyMed): Ozempic prescribing information, section 4
    “A personal or family history of MTC or in patients with MEN 2”
  48. 48.
    FDA label (DailyMed): Ozempic prescribing information, section 4
    “A serious hypersensitivity reaction to semaglutide or to any of the excipients in OZEMPIC. Serious hypersensitivity reactions including anaphylaxis and angioedema have been reported with OZEMPIC”
  49. 49.
    FDA label (DailyMed): Ozempic prescribing information, section 8.3
    “Discontinue OZEMPIC in women at least 2 months before a planned pregnancy due to the long washout period for semaglutide”
  50. 50.
    FDA label (DailyMed): Ozempic prescribing information, section 7.1
    “When initiating OZEMPIC, consider reducing the dose of concomitantly administered insulin secretagogue (such as sulfonylureas) or insulin to reduce the risk of hypoglycemia”
  51. 51.
    FDA label (DailyMed): Ozempic prescribing information, section 16
    “Each OZEMPIC multi-dose pen is for use by a single patient. An OZEMPIC pen must never be shared between patients, even if the needle is changed”
  52. 52.
    FDA label (DailyMed): Rybelsus and Ozempic tablets prescribing information, section 4
    “A personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)”
  53. 53.
    FDA label (DailyMed): Rybelsus and Ozempic tablets prescribing information, section 4
    “A prior serious hypersensitivity reaction to semaglutide or to any of the excipients in RYBELSUS or OZEMPIC tablets. Serious hypersensitivity reactions including anaphylaxis and angioedema have been reported with semaglutide tablets”
  54. 54.
    FDA label (DailyMed): Rybelsus and Ozempic tablets prescribing information, section 8.3
    “Discontinue RYBELSUS or OZEMPIC tablets in women at least 2 months before a planned pregnancy due to the long washout period for semaglutide”
  55. 55.
    FDA label (DailyMed): Rybelsus and Ozempic tablets prescribing information, section 8.2
    “advise patients that breastfeeding is not recommended during treatment with RYBELSUS or OZEMPIC tablets.”
  56. 56.
    FDA label (DailyMed): Rybelsus and Ozempic tablets prescribing information, section 7.2
    “Levothyroxine exposure was increased 33% (90% CI: 1.25 to 1.42) when administered with semaglutide tablets in a drug interaction study”
  57. 57.
    FDA label (DailyMed): Saxenda prescribing information, section 4
    “Patients with a personal or family history of medullary thyroid carcinoma (MTC) or patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)”
  58. 58.
    FDA label (DailyMed): Saxenda prescribing information, section 4
    “Patients with a serious hypersensitivity reaction to liraglutide or to any of the excipients in SAXENDA. Serious hypersensitivity reactions including anaphylactic reactions and angioedema have been reported with SAXENDA”
  59. 59.
    FDA label (DailyMed): Saxenda prescribing information, section 1
    “SAXENDA contains liraglutide. Coadministration with other liraglutide-containing products or with any other glucagon-like peptide-1 (GLP-1) receptor agonist is not recommended.”
  60. 60.
    FDA label (DailyMed): Saxenda prescribing information, section 8.1
    “Additionally, weight loss offers no benefit to a pregnant patient and may cause fetal harm. When a pregnancy is recognized, advise the pregnant patient of the risk to a fetus, and discontinue SAXENDA”
  61. 61.
    FDA label (DailyMed): Saxenda prescribing information, section 17
    “Inform patients that they should never share a SAXENDA pen with another person, even if the needle is changed. Sharing of the pen between patients may pose a risk of transmission of infection.”
  62. 62.
    FDA label (DailyMed): Mounjaro prescribing information, section 8.4
    “The safety and effectiveness of MOUNJARO have not been established in pediatric patients less than 10 years of age.”
  63. 63.
    FDA label (DailyMed): Trulicity prescribing information, section 8.4
    “The safety and effectiveness of TRULICITY have not been established in pediatric patients less than 10 years of age.”
  64. 64.
    FDA label (DailyMed): Foundayo prescribing information, section 8.4
    “Safety and effectiveness of FOUNDAYO have not been established in pediatric patients.”
  65. 65.
    FDA label (DailyMed): Trulicity prescribing information, section 8.7
    “However, there is limited clinical experience in patients with mild, moderate, or severe hepatic impairment; therefore, use TRULICITY with caution in these patient populations.”
  66. 66.
    FDA label (DailyMed): Mounjaro prescribing information, section 7.1
    “When initiating MOUNJARO, consider reducing the dose of concomitantly administered insulin secretagogues (e.g., sulfonylureas) or insulin to reduce the risk of hypoglycemia [see Warnings and Precautions (5.3)].”
  67. 67.
    FDA label (DailyMed): Trulicity prescribing information, section 7.2
    “When initiating TRULICITY, consider reducing the dose of concomitantly administered insulin secretagogues (such as sulfonylureas) or insulin to reduce the risk of hypoglycemia [see Warnings and Precautions (5.3) and Adverse Reactions (6.1)].”
  68. 68.
    FDA label (DailyMed): Foundayo prescribing information, section 7.2, Table 3
    “When initiating FOUNDAYO, consider reducing the dose of concomitantly administered insulin or insulin secretagogues (e.g., sulfonylureas) [see Warnings and Precautions (5.5)].”
  69. 69.
    FDA label (DailyMed): Mounjaro prescribing information, section 7.2
    “MOUNJARO delays gastric emptying and thereby has the potential to impact the absorption of concomitantly administered oral medications. Caution should be exercised when oral medications are concomitantly administered with MOUNJARO.”
  70. 70.
    FDA label (DailyMed): Trulicity prescribing information, section 7.1
    “TRULICITY delays gastric emptying and thus has the potential to reduce the rate of absorption of concomitantly administered oral medications.”
  71. 71.
    FDA label (DailyMed): Foundayo prescribing information, section 7.3
    “FOUNDAYO delays gastric emptying and thereby has the potential to impact the absorption of concomitantly administered oral medications [see Clinical Pharmacology (12.3)].”
  72. 72.
    FDA label (DailyMed): Ozempic prescribing information, section 7.2
    “OZEMPIC causes a delay of gastric emptying, and thereby has the potential to impact the absorption of concomitantly administered oral medications.”
  73. 73.
    FDA label (DailyMed): Saxenda prescribing information, section 7.1
    “SAXENDA causes a delay of gastric emptying, and thereby has the potential to impact the absorption of concomitantly administered oral medications.”
  74. 74.
    FDA label (DailyMed): Rybelsus and Ozempic tablets prescribing information, section 17
    “Advise females not to breastfeed during treatment with RYBELSUS or OZEMPIC tablets”